Navigation Links
Disarming specialized stem cells might combat deadly ovarian cancer
Date:1/27/2010

Eliminating cancer stem cells (CSCs) within a tumor could hold the key to successful treatments for ovarian cancer, which has been notoriously difficult to detect and treat, according to new findings published this week in the journal Oncogene by Yale School of Medicine researchers.

"We found that stopping the expression of two genesLin28 and Oct4reduces ovarian cancer cell growth and survival," said Yingqun Huang, M.D., assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine.

Ovarian cancer has been challenging to treat because it tends to recur frequently and develop resistance to treatment. The poor outcome for women with ovarian cancer has been associated with subtle and nonspecific symptomsearning it the moniker the "disease that whispers."

"This recurrence and drug resistance may be due to the presence of CSCs within the tumors that have the capacity to reproduce and to differentiate into non-CSC tumor cells that repopulate the tumor mass," said Huang, who is a member of Yale Stem Cell Center and Yale Cancer Center. "Eliminating these CSCs may be key to successful treatments."

While in the process of studying the functions of stem cell proteins in human embryonic stem cells, Huang and her colleagues unexpectedly discovered that a sub-population of ovarian cancer cells express stem cell proteins Lin28 and Oct4. They also found that the two proteins appear to act together in ovarian cancer tissue cells to produce more advanced tumors. Inhibiting their combined expression led to a significant decrease in the growth and survival of cancer cells. A larger-scale ovarian cancer study is currently underway to confirm the significance of the findings.

"We hope we will soon be able to apply this new information to improve outcomes, perhaps by developing better diagnostic markers and treatment strategies that may be useful in customizing treatment for ovarian cancer patients," said Huang.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Related biology news :

1. UB specialized exercise regimen shown to relieve prolonged concussion symptoms
2. Asthma and other allergies tied to absence of specialized cells
3. Mice use specialized neurons to detect carbon dioxide in the air
4. March of Dimes awards $250,000 prize to scientist who discovered how to reprogram human cells
5. Grant to study how cells sense electric fields
6. NYSCF Fellow lead author on study that creates blood vessel cells from stem cells
7. New way to generate abundant functional blood vessel cells from human stem cells discovered
8. Update on pluripotent stem cells (hESC and iPS)
9. Excess DNA damage found in cells of patients with Friedreichs ataxia
10. Mutations in different cells cooperate to set the stage for cancer
11. Study shows that delivering stem cells improves repair of major bone injuries in rats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology: